What Does Kyverna Therapeutics Do?

Total employees139
HeadquartersEmeryville
Founded2018

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing and delivering transformative cell therapies for autoimmune diseases. Leveraging its expertise in T-cell engineering, Kyverna is advancing a pipeline of novel, wholly-owned therapeutic candidates designed to address the underlying causes of these debilitating conditions. Their lead candidate, KYV-101, is an autologous, fully human CD19 CAR T-cell product candidate being investigated for lupus nephritis and other B cell-driven autoimmune diseases. Kyverna aims to provide new hope and improved outcomes for patients with limited treatment options.

Where Is Kyverna Therapeutics's Headquarters?

HQ Function

The headquarters serves as the central hub for Kyverna's research and development, clinical operations, corporate strategy, and administrative functions.

Notable Features:

The facility includes modern laboratory spaces for cell therapy research and development, along with collaborative office environments designed to foster innovation.

Work Culture:

Kyverna fosters a science-driven, patient-focused, and collaborative work culture. Employees are passionate about advancing novel therapies and working together to tackle complex scientific challenges in autoimmune disease.

HQ Significance:

Its location in the Bay Area provides access to a rich talent pool, leading research institutions, and a strong network of collaborators and investors crucial for a biotech company.

Values Reflected in HQ: The headquarters' design and functionality likely reflect Kyverna's commitment to cutting-edge science, collaboration, and operational excellence in pursuit of its therapeutic goals.

Location:

While Kyverna's primary physical operations are in the United States (Emeryville, CA and Waltham, MA), its global presence is expanding through its clinical trial activities. The company conducts multinational clinical studies for its therapeutic candidates, involving sites and patients in various countries to ensure diverse patient populations and accelerate development timelines. They also engage with the global scientific and medical community through publications, presentations, and collaborations.

Street Address:

1250 45th Street, Suite 350

City:

Emeryville

State/Province:

CA

Country:

USA

Where Else Does Kyverna Therapeutics Operate Around the World?

Waltham, MA/USA

Address: Undisclosed specific address, but presence confirmed for R&D/Technical Operations

To leverage the extensive biotech talent, research institutions, and infrastructure available in the Greater Boston area, complementing the Bay Area operations.

Buying Intent Signals for Kyverna Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Kyverna Therapeutics? Meet the Executive Team

As of April 2025, Kyverna Therapeutics' leadership includes:

Peter Maag, Ph.D. - Chief Executive Officer and Board Member
Dominic Borie, M.D., Ph.D. - President of Research and Development
Ryan Jones - Chief Financial Officer
Karen Zaderej - Chief Commercial Officer
Puja Sapra, Ph.D. - Chief Scientific Officer
Chandru Ramanarayanan - Chief Information Officer
James Chung, M.D., Ph.D. - Chief Medical Officer

Who's Investing in Kyverna Therapeutics?

Kyverna Therapeutics has been backed by several prominent investors over the years, including:

Gilead Sciences
Westlake Village BioPartners
Vida Ventures
Bain Capital Life Sciences
Surveyor Capital (a Citadel company)
Redmile Group
Farallon Capital Management
RTW Investments, LP
Wellington Management
RA Capital Management
Octagon Capital
Logos Capital

What Leadership Changes Has Kyverna Therapeutics Seen Recently?

Hire3
Exits0

Kyverna has significantly strengthened its executive team over the past 12-18 months, particularly leading up to and following its IPO, with key appointments in scientific, financial, and information leadership.

New Appointments:

Puja Sapra, Ph.D., Puja Sapra, Ph.D., appointed as Chief Scientific Officer to lead Kyverna's research and discovery efforts.
Chandru Ramanarayanan, Chandru Ramanarayanan appointed as Chief Information Officer to spearhead Kyverna's information technology strategy and infrastructure.
Ryan Jones, Ryan Jones appointed as Chief Financial Officer, bringing extensive financial leadership experience in the biopharmaceutical industry.

What Technology (Tech Stack) Is Used byKyverna Therapeutics?

Discover the tools Kyverna Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Kyverna Therapeutics Email Formats and Examples

Kyverna Therapeutics likely uses common corporate email formats. The most probable format is [first_initial][last]@[company_domain].com or [first].[last]@[company_domain].com.

[first_initial][last]@kyverna.com

Format

pjones@kyverna.com

Example

80%

Success rate

What's the Latest News About Kyverna Therapeutics?

Kyverna Therapeutics Press ReleaseJune 3, 2024

Kyverna Therapeutics Appoints Puja Sapra, Ph.D., as Chief Scientific Officer

Kyverna announced the appointment of Puja Sapra, Ph.D., as its Chief Scientific Officer. Dr. Sapra brings over 20 years of experience in oncology and immunology research and development....more

Kyverna Therapeutics Press ReleaseMay 20, 2024

Kyverna Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Kyverna reported its Q1 2024 financial results, highlighting progress in its KYV-101 clinical program for lupus nephritis and other autoimmune diseases, and a strong cash position following its IPO....more

Kyverna Therapeutics Press ReleaseFebruary 13, 2024

Kyverna Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kyverna announced the successful closing of its Initial Public Offering (IPO), raising approximately $366.9 million in gross proceeds. This funding will support the advancement of its cell therapy pipeline....more

Kyverna Therapeutics Press ReleaseJanuary 3, 2024

Kyverna Announces FDA Clearance of IND Application for KYV-101 for Patients with Myasthenia Gravis

Kyverna received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial of KYV-101 in patients with myasthenia gravis, expanding its clinical program....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Kyverna Therapeutics, are just a search away.